Data presented today show more participants achieved greater

Data presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trialBagsværd, Denmark, Thursday 22 September 2022 – Novo Nordisk today presented new data from the phase 3a ONWARDS 2 trial, demonstrating that 37% of adults with...

Related Keywords

Denmark , Sweden , Stockholm , , European Association For The Study Of Diabetes , Youtube , Linkedin , Twitter , Facebook , Novo Nordisk , Once Daily Insulin Degludec , Basal Insulin Treated Type , European Association , Annual Meeting , Research Study , Compare Two Types , New Weekly Insulin , Insulin Icodec , Available Daily Insulin , Insulin Degludec , People With Type , Who Use Daily Insulin ,